The United States Food and Drug Administration (USFDA) has concluded an inspection at Glenmark Pharmaceuticals’ formulation manufacturing facility-- Baddi, India. The inspection commenced on June 13, 2022 and concluded on June 22, 2022. USFDA has issued Form 483 with six observations after an inspection.
The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
